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Abstract  Drug  reaction  with  eosinophilia  and  systemic  symptoms  (DRESS)  syndrome  is  a
severe, idiosyncratic  reaction  characterized  by  diffuse  maculopapular  rash,  facial  edema,  lym-
phadenopathy,  fever,  eosinophilia  and/or  other  leukocyte  abnormalities,  and  involvement  of
internal organs  as  liver,  kidney,  heart  and  lung.
Diagnosing  this  entity  is  speciﬁcally  complicated  due  to  the  multiplicity  of  organs  involved.
DRESS syndrome  must  be  recognized  promptly  and  the  causative  drug  withdrawn  in  order  to
improve patient  outcomes.  Indeed,  it  is  a  potentially  life-threatening  condition,  with  a  reported
mortality between  5  and  20%.
We  describe  a  case  of  a  22-year  old  woman  admitted  to  our  hospital  with  acute  diffuse,
pruritic rash  associated  with  crampy  abdominal  pain,  vomiting,  diarrhea  and  fever  three  weeks
after starting  sulfasalazine  therapy.
Initially,  laboratory  parameters  revealed  normal  white  blood  cell  count  and  normal  liver
enzymes,  but  during  hospitalization,  eosinophilia  developed  and  liver  enzymes,  including
transaminases  and  cholestatic  parameters,  dramatically  increased.  The  diagnostic  of  DRESS  syn-
drome was  made  and  sulfasalazine  was  withdrawn  and  as  there  were  signs  of  disease  severity,
systemic  corticotherapy  was  initiated,  with  gradually  improvement  of  the  rash  and  symptoms
resolution.
The patient  was  discharged  home  after  thirty  days  of  hospitalization.
© 2016  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
PALAVRAS-CHAVE Hepatite  Aguda  na  Síndrome  DRESS
Doenc¸a Hepática
Induzida  por Resumo  A  síndrome  DRESS  (Drug  Reaction  with  Eosinophilia  and  Systemic  Symptoms)  é  uma
e  sistémica  caracterizada  por  dermatite  exfoliativa  e  rash  maculo-
re,  eosinoﬁlia  e  envolvimento  de  órgãos  internos,  como  o  fígado  e  o
gnóstico  é  difícil  porque  as  suas  manifestac¸ões  clínicas  mimetizamMedicamentos;
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Aguda/induzida
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papular, linfadenopatia,  feb
trato gastrointestinal.  O  diaquimicamente; as encontradas  noutras  doenc¸as  sistémicas  graves.
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Síndrome  de
Hipersensibilidade  a
Medicamentos;
Sulfassalazina/efeito
adverso
Esta  síndrome  deve  ser  reconhecida  precocemente  e  o  fármaco  responsável  suspenso  com  o
intuito de  melhorar  o  prognóstico  do  doente.  É,  de  facto,  uma  condic¸ão  potencialmente  fatal,
com uma  mortalidade  entre  5  e  20%.
Apresentamos  o  caso  clínico  de  uma  doente  de  22  anos,  que  recorreu  ao  servic¸o  de  urgência
por um  quadro  clínico  caracterizado  por  rash  pruriginoso  associado  a  dor  abdominal  tipo  cólica,
vómitos,  diarreia  e  febre  3  semanas  após  início  de  terapêutica  com  sulfassalazina.
Inicialmente,  a  avaliac¸ão  laboratorial  não  revelou  alterac¸ões,  mas  durante  o  internamento,
desenvolveu-se  eosinoﬁlia  e  as  provas  hepáticas,  incluindo  transaminases  e  parâmetros  de
colestase,  aumentaram  de  forma  signiﬁcativa.
Foi efetuado  o  diagnóstico  de  síndrome  de  DRESS,  a  sulfassalazina  foi  suspensa  e  iniciou
corticoterapia  sistémica,  dados  os  sinais  de  gravidade  da  doenc¸a.
Veriﬁcou-se  melhoria  gradual  da  sintomatologia,  tendo  tido  alta  clínica  após  trinta  dias  de
internamento.
© 2016  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este
e´ um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Drug  reaction  with  eosinophilia  and  systemic  symptoms
(DRESS)  syndrome  is  a  distinct,  severe,  idiosyncratic  reac-
tion  to  a  drug  characterized  by  a  prolonged  latency  period.1
The  estimated  incidence  of  this  syndrome  ranges  from  1
in  1000  to  1  in  10,000  drug  exposures.2
The  main  culprit  drugs  are  carbamazepine  and  allopuri-
nol,  even  though  almost  50  drugs  have  been  described  to
have  caused  this  syndrome.2
The  hallmark  features  of  DRESS  syndrome,  not  always
detectable  at  the  same  time,  include  diffuse  maculopapular
rash,  facial  edema,  lymphadenopathy,  fever,  hematologic
abnormalities  (eosinophilia  or  atypical  lymphocytes),3 and
involvement  of  internal  organs.4
It  is  difﬁcult  to  diagnose,  as  many  of  its  clinical  features
mimic  those  found  with  other  serious  systemic  disorders.5
However,  early  recognition  of  the  syndrome  with  the  cessa-
tion  of  the  causative  drug  is  essential  in  improving  patient
outcome.6
2. Clinical case
A  22-year  old  woman,  born  in  Cape  Verde,  was  being  fol-
lowed  in  the  rheumatology  outpatient  setting  for  migratory
oligoarthritis  for  seven  years.
For  this  reason,  sulfasalazine  was  started.  After  three
weeks  of  treatment,  she  was  admitted  to  our  emergency
department  with  an  acute  diffuse,  pruritic  rash.  On  admis-
sion,  sulfasalazine  was  withdrawn  and  hydrocortisone  was
administered.  Because  she  had  no  signs  of  end-organ  dam-
age  or  laboratory  abnormalities,  she  was  discharged  home.
After  3  days,  she  returned  to  our  emergency  department
with  the  same  clinical  picture,  now  with  crampy  abdominal
pain,  vomiting,  diarrhea  and  fever.On  admission,  mental  status  was  normal,  body  temper-
ature  was  36.3 ◦C,  blood  pressure  was  140/84  mmHg,  the
heart  rate  was  76  beats  per  minute.  She  was  alert  and  ori-
ented  and  in  no  apparent  distress.
-
h
iHer  skin  had  disseminated  dermatosis  with  papules;  there
ere  also  some  pustules  on  the  dorsal  area,  upper  and  lower
imbs.  There  was  no  evidence  of  lymphadenopaty  or  hep-
tosplenomegaly.
Laboratory  tests  showed  normal  white  blood  cell
ount  (6900  cell/L) with  absolute  eosinophil  count  of
300  cell/L, with  no  atypical  lymphocytes,  liver  parame-
ers  values:  aspartate  transaminase  (AST)  58  IU/L;  alanine
ransaminase  (ALT)  68  IU/L;  alkaline  phosphatase  (AP)
3  IU/L;  gamma-glutamyl  transferase  (gGT)  50  IU/L;  lactate
ehydrogenase  (LDH)  240  U/L;  total  bilirubin  0.25  mg/dL,
ith  a  normal  prothrombin  time  (PT);  serum  creatinine  level
f  1.01  mg/dL;  serum  urea  level  of  35  mg/dL;  C-reactive
rotein  6.64  mg/dL.
Dermatology  was  consulted  and  considered  the  skin
esions  could  be  due  to  acute  generalized  exanthematous
ustulosis  induced  by  sulfasalazine  (that  had  already  been
ithdrawn)  and  a  biopsy  of  one  of  the  skin  lesions  was  per-
ormed.  Based  on  this  diagnosis,  prednisolone  20  mg/day
nd  hydroxyzine  25  mg  tid  were  initiated,  with  gradually
mprovement  of  the  rash.
On  the  fourth  day  of  hospitalization,  she  developed
osinophilia  (5.6  ×  103/L),  liver  enzymes  raised  (AST
22  IU/L;  ALT  207  IU/L;  AP  184  IU/L;  gGT  217  IU/L;  LDH
18  U/L),  maintaining  fever  and  skin  rash.
Due  to  sore  throat  on  the  sixth  day  after  admission,  Oto-
aryngology  was  consulted  and  observed  tonsillitis  with  a
rayish-white  coating,  recommending  therapy  with  amoxi-
illin  and  clavulanic  acid.
Liver  enzymes  continued  increasing  reaching  maximum
alues  on  the  eleventh  day  of  hospitalization  (AST  3591  IU/L;
LT  2102  IU/L;  AP  573  IU/L;  gGT  1591  IU/L;  LDH  1940  U/L
otal  bilirubin  2.11  mg/dL,  also  with  elevation  of  PT  (27,
ith  normal  value  between  10  and  14).  Abdominal  ultra-
ound  revealed  only  portal  accentuation  pattern.  Due
o  the  suspicion  of  toxic  hepatitis,  antibiotherapy  was
ithdrawn.
Serologic  tests  for  acute  infection  by  hepatotropic  virus
-  hepatitis  A,  B,  C,  E,  Epstein--Barr  virus,  Citomegalovirus,
uman  herpesvirus  (HHV)-6  (evaluated  by  enzyme-linked
mmunosorbent  assay)  were  negative.
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Skin  biopsy  showed  superﬁcial  perivascular  lymphocytic
nﬁltration.
The  diagnosis  of  DRESS  syndrome  was  made  [using  RegiS-
AR  criteria,7 the  patient  had  4  characteristics  --  acute  skin
ash,  fever  (>38 ◦C),  involvement  of  liver,  and  eosinophils
bove  the  laboratory  limits)].  For  this  reason,  prednisolone
as  increased  to  60  mg/day  (1  mg/kg/day)  with  a  progres-
ive  improvement  in  the  rash.  Similarly,  liver  enzymes  which
tarted  reducing  gradually,  since  one  day  after  antibiother-
py  withdrawal,  returned  to  normal.
The  patient  was  discharged  home  after  thirty  days  of
ospitalization  (on  60  mg  prednisolone/day),  with  the  indi-
ation  to  gradually  reduce  corticosteroid  therapy  (slower
eduction).  After  three  months  of  follow-up,  now  on  40  mg
rednisolone/day,  the  rash  is  in  remission.
. Discussion
rug  Reaction  with  Eosinophilia  and  Systemic  Symptoms
DRESS)  syndrome  formed  by  the  acronym  derived  from
he  term  ‘‘Drug  Rash  with  Eosinophilia  and  Systemic  Symp-
oms’’,6 was  introduced  by  Bocquet  et  al.8 and  was  based
n  the  observation  of  Callot  et  al.9 who,  in  1996,  performed
 retrospective  study  of  24  patients:  three  patients  had
ad  subacute  papulonodular  or  inﬁltrated  plaques,  without
isceral  involvement,  while  the  remaining  21  patients  had
n  acute  widespread  eruption,  with  fever,  enlarged  lymph
odes,  and  multivisceral  involvement  developed  an  acute
ystemic  illness  with  eosinophilia.9
Although  a  dermatosis  is  common  in  DRESS,  the
xtent  of  skin  involvement  is  variable  and  therefore  the
R’  in  DRESS  was  subsequently  changed  from  ‘rash’  to
reaction’.6
The  pathogenesis  of  DRESS  syndrome  is  not  well
nderstood1 but  probably  involves  different  mechanisms,
ncluding  detoxiﬁcation  defects2 leading  to  reactive
etabolite  formation  and  subsequent  immunological  reac-
ions,  slow  acetylation,  and  reactivation1 of  human
erpes,10,11 including  Epstein--Barr  virus,  cytomegalovirus
nd  HHV-6  and  -7.2,12
Many  drugs  have  been  reported  to  cause  DRESS  syn-
rome.  Cacoub  et  al.,  using  the  RegiSCAR  scoring  system,
dentiﬁed  44  drugs  implicated  in  172  cases  reported
etween  January  1997  and  May  2009.2 In  this  systematic
eview,  the  most  common  culprit  drugs  were  aromatic  anti-
onvulsants  (carbamazepine,  phenobarbital,  phenytoin),
llopurinol,  lamotrigine,  sulfasalazine,  nevirapine,  abacavir
nd  mexiletine.2
This  syndrome  is  usually  characterized  by  long  latency
eriod  between  administration  of  the  offending  drug  and
ymptom  onset  with  a  mean  of  3.9  weeks  (range  0.5--16
eeks).13 The  delayed  onset  in  relation  to  introduction
f  the  causative  drug  is  one  of  the  important  features  of
RESS  that  can  be  distinguished  from  other  types  of  drug
ruptions.14
DRESS  syndrome  is  a  complex  syndrome  with  a  broad
pectrum  of  clinical  features.1 The  reaction  often  starts  with
ever  shortly  followed  by  rash,  which  is  usually  pruritic,  and
ariable  degrees  of  lymphadenopathy.14
The  cutaneous  eruption  consists  of  a  morbilliform
ash.6 Initially,  the  upper  trunk,  face,  upper  extremities
c
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re  affected  and  followed  by  involvement  of  lower
xtremities.14
Swelling  of  the  face,  with  marked  periorbital  involve-
ent  occurs  in  about  25%  of  patients.6 Tender  lym-
hadenopathy  can  be  seen  in  most  patients  (70--75%)6 early
n  the  illness,  affecting  predominantly  cervical  nodes  or  gen-
ralized.  Bilateral  swelling  of  salivary  glands  with  severe
erostomia  is  frequently  observed.14
Other  features  of  DRESS  include  visceral  involve-
ent  (hepatitis,  pneumonitis,  myocarditis,  pericarditis,6
ephritis,  pancreatitis,11 encephalitis,11,14 thyroiditis,14
olitis6).12,15 The  liver  is  reported  to  be  the  most  frequently
nvolved  internal  organ.1,2,16
There  have  been  proposed  three  different  diagnos-
ic  criteria.1,11 According  to  Bocquet  et  al.  (in  1996),
he  diagnosis  is  established  if  there  are  at  least  three
riteria  present:  skin  eruption,  hematologic  abnormalities
eosinophilia  >1500/mm3; presence  of  atypical  lympho-
ytes),  and  systemic  involvement,  including  adenopathies
>2  cm  in  diameter),  hepatitis  (transaminase  elevation  of  at
east  twice  the  normal  values),  interstitial  nephritis,  inter-
titial  pneumonia,  or  carditis.8 The  Japanese  study  group
f  severe  cutaneous  adverse  reactions  to  drugs  (SCAR-J)
riteria  established  other  criteria  (in  2006):  maculopapular
ash  developing  >3  weeks  after  starting  with  the  suspected
rug,  prolonged  clinical  symptoms  two  weeks  after  dis-
ontinuing  the  causative  drug,  fever  (>38 ◦C),  elevation
f  liver  enzyme  (ALT  >100  U/L),  leukocytosis  abnormal-
ties  [leukocytosis  (>11  ×  103/L),  atypical  lymphocytosis
>5%)  or  eosinophilia  (>1.5  ×  103/L)],  lymphadenopathy,
nd  HHV-6  reactivation.  Diagnosis  of  typical  DRESS  requires
he  presence  of  all  7  criteria.17 The  European  registry  of
evere  cutaneous  adverse  reactions  to  drugs  and  collec-
ion  of  biological  samples  (RegiSCAR)  group  suggested  the
ollowing  criteria  (in  2007)  for  hospitalized  patients:  reac-
ion  suspected  to  be  drug  related,  acute  skin  rash,  fever
bove  38 ◦C,  enlarged  lymph  nodes  at  at  least  two  sites,
nvolvement  of  at  least  one  internal  organ,  blood  count
bnormalities:  lymphocytes  above  or  below  the  laboratory
imits,  eosinophils  above  the  laboratory  limits  (in  percentage
r  absolute  count),  or  platelets  below  the  laboratory  limits.
t  least  3  of  these  criteria  should  be  present  for  DRESS.7
According  to  RegiSCAR  criteria,  the  patient  described
ere  met  4  characteristics:  acute  skin  rash,  fever,  involve-
ent  of  liver  and  eosinophilia.
The  diagnosis,  as  shown  in  this  clinical  case,  can  be
ifﬁcult  because  many  of  the  clinical  features  can  be
onspeciﬁc,  and  the  syndrome  often  mimics  infections
particularly  bacteremia),  neoplastic  diseases  (lymphoma,
eukemia,  hypereosinophilic  syndrome,  paraneoplastic),
utoimmune  or  connective  tissue  conditions  (adult-onset
till’s  disease,  lupus  erythematosus,  vasculitis).6,10,11,15
Although  no  deﬁnitive  laboratory  test  exists  for  DRESS,
 complete  blood  cell  count  can  identify  the  characteristic
eukocytosis  with  eosinophilia.18 Nevertheless,  leukopenia
nd  lymphopenia  have  been  also  reported  and  they  occa-
ionally  precede  leukocytosis.14
Hepatitis  with  isolated  elevation  of  liver  transaminases  is
ommon.6 A  cholestatic  injury  pattern  is  seen  in  a  minority
f  patients.19
Although  the  bilirubin  may  be  normal  at  presentation,
yperbilirubinemia  can  develop  even  after  the  causative
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drug  is  discontinued.  Elevations  in  liver  enzymes  usually  con-
tinue  to  persist  for  several  days  after  discontinuation  of  the
offending  drug.14
Liver  failure,  although  rare,  contributes  to  the  leading
causes  of  death.6
The  skin  biopsy  may  help  to  conﬁrm  the  diagnosis  but
is  nonspeciﬁc.10,20 It  shows  a  non-speciﬁc  lymphocytic  inﬁl-
trate  of  the  papillary  dermis,  which  may  contain  eosinophils
and  which  is  generally  denser  than  in  other  drug  reactions.20
DRESS  syndrome  must  be  recognized  promptly  and  the
causative  drug  withdrawn.1,21,22 Indeed,  it  has  been  reported
that  the  earlier  the  drug  withdrawal,  the  better  the
prognosis.1
However,  clinical  symptoms  can  be  prolonged  even  after
the  withdrawal  of  culprit  drugs.  In  fact,  in  the  study  per-
formed  by  Kim  et  al.,  which  included  48  patients  with  DRESS
syndrome,  clinical  manifestations  persisted  for  1  month.16
Empirical  treatment  with  antibiotics  or  anti-inﬂammatory
drugs  should  not  be  administered  during  the  acute  disease,
since  they  may  confuse  or  worsen  the  clinical  picture  of
patients  due  to  an  unexplained  cross-reactivity  between
drugs,14 as  succeeded  in  our  patient.
In  2010,  the  French  Society  of  Dermatology  published
a  consensus  on  the  management  of  DRESS  syndrome.
According  to  this  consensus,  the  absence  of  signs  of
severity,  they  recommend  topical  corticosteroids,  emol-
lients  and  H1-antihistamines.  In  the  presence  of  signs  of
severity  (transaminases  greater  than  ﬁve  times  normal,
renal  impairment,  pneumonia,  haemophagocytosis  or  car-
diac  involvement),  they  propose  corticosteroids  equivalent
to  1  mg/kg  per  day  of  prednisolone.  If  there  are  life-
threatening  signs:  haemophagocytosis  with  bone  marrow
failure,  encephalitis,  severe  hepatitis,  renal  failure,  respi-
ratory  failure),  they  suggest  steroids  generally  associated
with  intravenous  immunoglobulin  (IVIG)  at  a  dose  of  2  g/kg
over  5  days.  Finally,  in  the  presence  of  signs  of  severity  with
conﬁrmation  of  major  viral  reactivation,  they  recommend
combining  steroids  and  antiviral  (ganciclovir)  and/or  IVIG.21
In  this  case,  there  were  signs  of  severity  as  transaminases
were  greater  than  ﬁve  times  normal.  For  this  reason,  cor-
ticotherapy  was  initiated  with  a  good  response,  albeit  the
difﬁculty  in  doing  the  diagnosis.
The  mortality  rate  is  reported  to  be  between  52 and
20%6,22,23 and  has  been  correlated  with  the  degree  of  hepatic
or  renal  involvement.14
Ethical disclosures
Protection  of  human  and  animal  subjects.  The  authors
declare  that  no  experiments  were  performed  on  humans  or
animals  for  this  study.
Conﬁdentiality  of  data.  The  authors  declare  that  they  have
followed  the  protocols  of  their  work  center  on  the  publica-
tion  of  patient  data.Right  to  privacy  and  informed  consent.  The  authors  have
obtained  the  written  informed  consent  of  the  patients  or
subjects  mentioned  in  the  article.  The  corresponding  author
is  in  possession  of  this  document.
1307
onﬂicts of interest
he  authors  have  no  conﬂicts  of  interest  to  declare.
eferences
1. Choudhary S, McLeod M, Torchia D, Romanelli P. Drug Reaction
with Eosinophilia and Systemic Symptoms (DRESS) syndrome. J
Clin Aesthet Dermatol. 2013;6:31--7.
2. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L,
et al. The DRESS syndrome: a literature review. Am J Med.
2011;124:588--97.
3. El Omairi N, Abourazzak S, Chaouki S, Atmani S, Hida M.
Drug Reaction with Eosinophilia and Systemic Symptom (DRESS)
induced by carbamazepine: a case report and literature review.
Pan Afr Med J. 2014;2:18--9.
4. Girelli F, Bernardi S, Gardelli L, Bassi B, Parente G, Dubini
A, et al. A new case of DRESS syndrome induced by sul-
fasalazine and triggered by amoxicillin. Case Rep Rheumatol.
2013;2013:409152.
5. Fleming P, Marik PE. The DRESS syndrome: the great clinical
mimicker. Pharmacotherapy. 2011;31:332.
6. Criado PR, Criado RF, Avancini JM, Santi CG. Drug reaction with
Eosinophilia and Systemic Symptoms (DRESS)/Drug-induced
Hypersensitivity Syndrome (DIHS): a review of current concepts.
An Bras Dermatol. 2012;87:435--49.
7. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici
BB, Mockenhaupt M, et al. Variability in the clinical pattern of
cutaneous side-effects of drugs with systemic symptoms: does a
DRESS syndrome really exist? Br J Dermatol. 2006;156:609--11.
8. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolym-
phoma and drug hypersensitivity syndrome (drug rash with
eosinophilia and systemic symptoms: DRESS). Semin Cutan Med
Surg. 1996;15:250--7.
9. Callot V, Roujeau JC, Bagot M, Wechsler J, Chosidow O,
Souteyrand P, et al. Drug-induced pseudolymphoma and hyper-
sensitivity syndrome. Two different clinical entities. Arch
Dermatol. 1996;132:1315--21.
0. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clin
Perspect. 2013;68:693, e1--14; quiz 706--8.
1. Fernando SL. Drug-reaction eosinophilia and systemic symptoms
and drug-induced hypersensitivity syndrome. Australas J Der-
matol. 2014;55:15--23.
2. Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guil-
laume JC, et al. Twelve-year analysis of severe cases of drug
reaction with eosinophilia and systemic symptoms: a cause
of unpredictable multiorgan failure. Arch Dermatol. 2009;145:
67--72.
3. Alkhateeb H, Said S, Cooper CJ, Gaur S, Porres-Aguilar M. DRESS
syndrome following ciproﬂoxacin exposure: an unusual associa-
tion. Am J Case Rep. 2013;14:526--8.
4. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity
syndrome (DIHS): a reaction induced by a complex interplay
among herpesviruses and anti-drug immune responses. Allergol
Int. 2006;55:1--8.
5. Giri PP, Roy S, Bhattyacharya S, Pal P, Dhar S. Dress syndrome
with sepsis, acute respiratory distress syndrome and pneumo-
mediastinum. Indian J Dermatol. 2011;56:763--5.
6. Kim DH, Koh YI. Comparison of diagnostic criteria and determi-
nation of prognostic factors for drug reaction with eosinophilia
and systemic symptoms syndrome. Allergy Asthma Immunol Res.
2014;6:216--21.7. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a
DRESS syndrome has been sufﬁciently established on the basis of
typical clinical features and viral reactivations. Br J Dermatol.
2007;156:1083--4.
31
1
2
2
2
208  
8. Tsyrulnik A, Landman A. Drug Rash with Eosinophilia and Sys-
temic Symptoms: two emergency department cases. West J
Emerg Med. 2011;12:559--62.
9. Cardoso CS, Vieira AM, Oliveira AP. DRESS syndrome: a case
report and literature review. BMJ Case Rep. 2011;3:2011.
0. Tas S, Simonart T. Management of drug rash with eosinophilia
and systemic symptoms (DRESS syndrome): an update. Derma-
tology. 2003;206:353--6.
1. Descamps V, Ben-Saïd B, Sassolas B, Truchetet F, Avenel-
Audran M, Girardin P, et al. Management of drug reaction withA.M.  Oliveira  et  al.
eosinophilia and systemic symptoms (DRESS). Ann Dermatol
Venereol. 2010;137:703--8.
2. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and
systemic symptoms: a retrospective study of 60 cases. Arch
Dermatol. 2010;146:1373--9.
3. Chiou CC, Yang LC, Hung SI, Chang YC, Kuo TT, Ho HC,
et al. Clinicopathological features and prognosis of drug rash
with eosinophilia and systemic symptoms: a study of 30
cases in Taiwan. J Eur Acad Dermatol Venereol. 2008;22:
1044--9.
